Short Interest in Kamada Ltd. (NASDAQ:KMDA) Grows By 8.9%

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 29,300 shares, an increase of 8.9% from the October 31st total of 26,900 shares. Based on an average daily trading volume, of 34,400 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KMDA. Y.D. More Investments Ltd increased its position in Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after purchasing an additional 690,842 shares during the period. Vanguard Group Inc. boosted its stake in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in shares of Kamada during the third quarter worth $117,000. Finally, Public Employees Retirement System of Ohio bought a new position in Kamada during the third quarter worth $77,000. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Stock Performance

KMDA stock opened at $5.96 on Wednesday. The company has a market capitalization of $342.58 million, a P/E ratio of 21.29 and a beta of 0.99. The company has a fifty day moving average price of $5.59 and a 200-day moving average price of $5.49. Kamada has a 52-week low of $4.66 and a 52-week high of $6.53.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, November 14th. StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 27th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.